Quantitation of bergenin in human plasma by liquid chromatography/tandem mass spectrometry.
This paper reports the development and validation of an assay for quantitation of bergenin in human plasma using liquid chromatography/tandem mass spectrometry (LC-MS/MS). Bergenin and the internal standard (I.S.), 5-bromo-2,4(1H,3H)-pyrimidinedione (5-BrU), were separated by reversed phase HPLC and quantitated by MS/MS using electrospray ionization (ESI) and multiple reaction monitoring (MRM) in the negative ion mode. The most intense [M-H](-) MRM transition of bergenin at m/z 326.9-->312.3 was used for quantitation and the transition at m/z 188.9-->42.2 was used to monitor 5-BrU. Stability issues with bergenin required the addition of ascorbic acid to plasma samples prior to storage and analysis within 10 days storage at -80 degrees C. The method was linear in the range 3-1000 ng/mL with intra- and inter-day precision of 3.94-5.96 and 1.62-8.31%, respectively, and accuracy <2.33%. The assay was successfully applied to a pharmacokinetic study in healthy volunteers after administration of a single 250 mg oral dose.
Yu
Weisong
W
Research Center for Drug Metabolism, College of Life Science, Jilin University, Changchun 130023, PR China.
Wang
Yingwu
Y
Zhang
Yunhui
Y
Zhang
Dan
D
Lan
Jing
J
Liu
Zeyuan
Z
Gu
Jingkai
J
Fawcett
J Paul
JP
D000328:Adult; D001578:Benzopyrans / Q000097:blood* / Q000493:pharmacokinetics; D002853:Chromatography, Liquid / Q000379:methods*; D006801:Humans; D008297:Male; D012015:Reference Standards; D053719:Tandem Mass Spectrometry / Q000379:methods*
D001578:Benzopyrans; C006741:bergenin